NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/14/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,903.42 mln
Float304 mln
Earnings Date08/12/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
1.72
Highly suspicious
1-Year Forecast
14.17
Transformational upside
Relative Strength
87
/ 100
Strongly outperforming
Debt / Equity
0.01
Debt-free
ROE
-379
Deeply negative
Business Description
AtaiBeckley Inc. is a New York-based company founded in 2018 that works to develop new treatments for mental health conditions, operating across the United States, Germany, and Canada. The company focuses on a broad range of experimental medicines targeting conditions such as depression, anxiety, schizophrenia, and alcohol use disorder, with several drugs currently in clinical trials. Many of its treatments are based on psychedelic or psychedelic-inspired compounds, reflecting a growing scientific interest in this area of medicine.
